Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor.

Buhrman JD, Jordan KR, Munson DJ, Moore BL, Kappler JW, Slansky JE.

J Biol Chem. 2013 Nov 15;288(46):33213-25. doi: 10.1074/jbc.M113.509554. Epub 2013 Oct 8.

2.

Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens.

Buhrman JD, Jordan KR, U'ren L, Sprague J, Kemmler CB, Slansky JE.

Cancer Res. 2013 Jan 1;73(1):74-85. doi: 10.1158/0008-5472.CAN-12-1005. Epub 2012 Nov 16.

3.

Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens.

Jordan KR, McMahan RH, Kemmler CB, Kappler JW, Slansky JE.

Proc Natl Acad Sci U S A. 2010 Mar 9;107(10):4652-7. doi: 10.1073/pnas.0914879107. Epub 2010 Jan 26. Erratum in: Proc Natl Acad Sci U S A. 2010 Mar 9;107(10):4788-9.

4.

Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines.

McMahan RH, McWilliams JA, Jordan KR, Dow SW, Wilson DB, Slansky JE.

J Clin Invest. 2006 Sep;116(9):2543-51. Epub 2006 Aug 24.

5.

TCR hypervariable regions expressed by T cells that respond to effective tumor vaccines.

Jordan KR, Buhrman JD, Sprague J, Moore BL, Gao D, Kappler JW, Slansky JE.

Cancer Immunol Immunother. 2012 Oct;61(10):1627-38. Epub 2012 Feb 21.

6.

Improving T cell responses to modified peptides in tumor vaccines.

Buhrman JD, Slansky JE.

Immunol Res. 2013 Mar;55(1-3):34-47. doi: 10.1007/s12026-012-8348-9. Review.

7.

Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.

Pedersen SR, Sørensen MR, Buus S, Christensen JP, Thomsen AR.

J Immunol. 2013 Oct 1;191(7):3955-67. doi: 10.4049/jimmunol.1300555. Epub 2013 Sep 9.

8.

Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.

Akiyama Y, Maruyama K, Tai S, Takikawa M, Ohshita C, Yamamoto A, Yamazaki N, Kiyohara Y, Yamaguchi K.

Int J Oncol. 2008 Sep;33(3):433-41.

PMID:
18695871
9.

Epitope-specific antibody response to Mel-CAM induced by mimotope immunization.

Hafner C, Wagner S, Jasinska J, Allwardt D, Scheiner O, Wolff K, Pehamberger H, Wiedermann U, Breiteneder H.

J Invest Dermatol. 2005 Jan;124(1):125-31.

10.

Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes.

Riemer AB, Förster-Waldl E, Brämswig KH, Pollak A, Zielinski CC, Pehamberger H, Lode HN, Scheiner O, Jensen-Jarolim E.

Eur J Immunol. 2006 May;36(5):1267-74.

11.

A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination.

Speiser DE, Baumgaertner P, Barbey C, Rubio-Godoy V, Moulin A, Corthesy P, Devevre E, Dietrich PY, Rimoldi D, Liénard D, Cerottini JC, Romero P, Rufer N.

J Immunol. 2006 Jul 15;177(2):1338-48.

12.

Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.

Corbière V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethé B, van Baren N, Van den Eynde BJ, Boon T, Coulie PG.

Cancer Res. 2011 Feb 15;71(4):1253-62. doi: 10.1158/0008-5472.CAN-10-2693. Epub 2011 Jan 7.

13.

Development, characterization, and immunotherapeutic use of peptide mimics of the Thomsen-Friedenreich carbohydrate antigen.

Heimburg-Molinaro J, Almogren A, Morey S, Glinskii OV, Roy R, Wilding GE, Cheng RP, Glinsky VV, Rittenhouse-Olson K.

Neoplasia. 2009 Aug;11(8):780-92.

14.

Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.

Karan D, Dubey S, Van Veldhuizen P, Holzbeierlein JM, Tawfik O, Thrasher JB.

Immunotherapy. 2011 Jun;3(6):735-46. doi: 10.2217/imt.11.59.

PMID:
21668311
15.

Genetic engineering of T cell specificity for immunotherapy of cancer.

Willemsen RA, Debets R, Chames P, Bolhuis RL.

Hum Immunol. 2003 Jan;64(1):56-68. Review.

PMID:
12507815
17.

Translational development of active immunotherapy for hematologic malignancies.

Kwak LW.

Int J Hematol. 2002 Aug;76 Suppl 1:320-1. Review.

PMID:
12430873
18.

Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.

Gatza E, Okada CY.

J Immunol. 2002 Nov 1;169(9):5227-35. Erratum in: J Immunol. 2003 May 15;170(10):following 5332.

19.

[Inhibitory effect of dendritic cells pulsed with MAGE-3 peptide on transplanted murine gastric cancer in mice].

Lü B, Liu BY, Zhang Y, Chen XH, Zhu ZG, Yin HR, Lin YZ.

Zhonghua Yi Xue Za Zhi. 2005 Aug 10;85(30):2120-3. Chinese.

PMID:
16313822
20.

T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells.

Tan MP, Gerry AB, Brewer JE, Melchiori L, Bridgeman JS, Bennett AD, Pumphrey NJ, Jakobsen BK, Price DA, Ladell K, Sewell AK.

Clin Exp Immunol. 2015 May;180(2):255-70. doi: 10.1111/cei.12570.

Supplemental Content

Support Center